ClinicalTrials.gg
CompletedNCT04145544NEOARTUpdated Aug 19, 2025Results posted

A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.

An interventional study of Implantation of the ArtiFascia® and Implantation of other commercial suturable dural substitute in Dural Tear and Cerebrospinal Fluid Leak, sponsored by Nurami Medical Ltd. Completed at 9 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Nurami Medical Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study was to evaluate the safety and effectiveness of ArtiFascia® in comparison with commercially available dural substitutes in subjects requiring Dural repair following neurosurgery.

Subjects with planned cranial neurosurgery participated in this study. During the surgery the dura is likely to be cut and damaged. A damaged dura can cause a leakage of brain fluids (cerebrospinal fluid [CSF] leakage) and increase the risk of infections. The damaged dura can be fixed with dural patch like ArtiFascia®. ArtiFascia® is a bioabsorbable medical synthetic dural replacement that aids in the regeneration of a new dura. Furthermore, it incorporates a sealing layer capable of minimizing CSF leakage and infection.

Read the detailed description

A Prospective, randomized, controlled multi-center study of ArtiFascia® Dural repair patch compared with commercially available dural substitutes- NEOART Study.

The dura mater is a fibrous connective tissue that surrounds the nervous system (brain and spinal cord) and provides a mechanical barrier that contains the cerebrospinal fluid (CSF). The dura mater may be damaged as a result of trauma or planned surgery. When dural defects cannot be repaired by primary closure, a dural substitute must be utilized in order to reduce CSF leakage.

There are devices that have been used as dural substitutes. Among the devices that are based on natural raw materials, collagen-based matrices are widely used. Although collagen was proven to be biocompatible, using collagen-based materials still possess several limitations such as CSF leaks. Synthetic dural substitutes are also used to repair dura mater. The most widely used raw-material for these synthetic products are polyesters - resorbable and biocompatible polymers. There are several dural substitutes based on synthetic polyesters that were successfully tested pre-clinically as well as in human studies.

Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a polymeric synthetic dural substitute that is absorbed by the body.

Before the study, all subjects underwent neurological assessment. Only subjects that were found to be suitable to participate in the study, and agree to participate, were randomly allocated into one of the following groups:

  • Experimental group (ArtiFascia® device);
  • Control group (Other commercially available suturable dural substitutes).

The Sponsor was blinded to treatment. The subjects underwent the planned surgery and at the end the investigator used ArtiFascia® patch or standard dural substitute to repair the damaged Dura. ArtiFascia® graft was placed in areas where the native dural layer was damaged or missing. ArtiFascia® was applied via a routine and well-known procedure, using a suturing technique. After implantation, the porous fibrous structure of ArtiFascia® provides a scaffold, which enables infiltration of fibroblasts and cells from the intact tissue, ultimately replacing damaged dural tissue. The patch is expected to resorb within a few months and to be replaced by the native tissue with complete dural closure.

During the surgery and until subject's release from the hospital the subject's health was closely monitored. Before the discharge subjects underwent neurological examination. Subjects had been followed up at 4-6 weeks and at 6 months post surgery.

At each follow up visit physical and neurological examinations were performed. Radiographic Evaluation (Magnetic Resonance Imaging) was performed at 6 months post operation.

A total of 92 subjects from 7 sites in Europe were enrolled and implanted with test or control device.

The primary endpoint was achieved when the final study subject has completed a 6-months follow-up.

02

Conditions studied

  • Dural Tear
  • Cerebrospinal Fluid Leak
03

In context

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

This study's enrollment of 92 is above the median of 74 across 24 interventional studies indexed under Cerebrospinal Fluid Leak.

Browse Cerebrospinal Fluid Leak studies →

Lead sponsor

Nurami Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject between the ages of 18-75
  2. Subject is scheduled for an elective cranial surgery with a dural damage that can be completely repaired/closed by a suture-able dural substitute (ArtiFascia device or other commercially available dural substitutes)
  3. Subject has undergone radiographic imaging (such as, MRI) in the past 6 months before enrolment
  4. Surgical wound is expected to be Class I/clean
  5. Subject understands the study requirements and the treatment procedures and provides written before any study-specific tests or procedures are performed
  6. Subject is able and willing to adhere to the required follow-up visits and testing

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women or interest in becoming pregnant during the duration of the study
  2. Subject has known hydrocephalus
  3. Subject is unable to undergo MRI after the surgery
  4. Subject's is less than 12 months
  5. Subject has a local or systemic infection (e.g. urinary tract infection (UTI), active pneumonia) or evidence of any surgical site infection, fever > 38.3℃, positive blood culture and/or a positive chest x-ray for acute infectious process
  6. Subject will require use of dural adhesive or sealant
  7. Subject is intended to undergo craniectomy wherein bone flap will not be returned
  8. Subject with suspected low success in wound healing due to past treatments (e.g. chemotherapy, radiation therapy, severe diabetes etc.) or other conditions (e.g. severe peripheral vascular disease, long standing treatment)
  9. Subject has been clinically diagnosed with (other than basal cell carcinoma or low-grade glioma), uncontrolled diabetes (>6.5%), sepsis, systemic collagen disease.
  10. Subject had chemotherapy and/or radiotherapy in the past 12 weeks before surgery or is planned to have chemotherapy or radiotherapy less than 12 weeks after surgery.
  11. Subject is an acute cranial trauma surgical case
  12. Subjects with a concurrent disease that would place the patient in excessive risk to the planned surgery
  13. Subject had a previous neurosurgery in the same anatomical site
  14. Subject with other undesirable symptoms defined by the principal investigator
  15. Patient has coagulopathy as determined by the surgeon
  16. Subject is participating in another clinical trial using similar devices/drugs
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Treatment arm

    Procedure was performed under general anesthesia. The subjects underwent the planned surgery. At the end of the surgery, the investigator used the ArtiFascia® patch. Implantation of the ArtiFascia® was according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Post operation the subject stayed at the hospital according to site standards and physician discretion.

    Device: Implantation of the ArtiFascia®

  • Active comparator
    Control

    Same procedure as for the treatment arm but using a commercial suturable dural substitute. Implantation of the commercial suturable dural substitute was according to clinical discretion of the physician, and in compliance with each specific device instructions for use.

    Device: Implantation of other commercial suturable dural substitute

Interventions

  • DeviceImplantation of the ArtiFascia®

    Following are the general instructions for use for the ArtiFascia®: * Cut the ArtiFascia® to the required shape under aseptic conditions * Apply ArtiFascia® to the damaged area * Suture the ArtiFascia® in place * Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision. Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.

  • DeviceImplantation of other commercial suturable dural substitute

    Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use

06

What researchers measure

Primary outcomes

  1. Absence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging.

    The primary end point will be assessed by evaluating the absence of cerebrospinal fluid fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging and physical examination of the surgical site.

    Time frame: 6 month.

Secondary outcomes

  1. Wound Healing Assessment

    Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.

    Time frame: 6 month follow-up

  2. Device Handling Characteristics as Reported by a User Experience Questionnaire

    The following scoring system was used for the evaluation: 1\) Device ease of use, suturing and cutting were evaluated on a scale of 1=Easy to 5=Difficult. 2) Device strength and seal quality (during implantation) were scored on scale of 1=Low to 5=High.

    Time frame: On the day of the surgical procedure

  3. Radiological Imaging at 6 Months for Additional Findings at Implant Site

    The rate of each of the following: Extracerebral fluid accumulation, pseudomeningocele, adhesion formation, brain edema adjacent to device implant site, abnormal thickening at implantation site and new membrane (scar) formation.

    Time frame: 6 month follow-up

07

Results

Posted Aug 19, 2025
Limitations and caveats
No limitations.

Participant flow

The clinical trial was performed in 8 European medical centers (Poland, Czech Republic, Spain and Belgium) and in 1 Israeli medical center. Subjects were enrolled from January 2020 to January 2022.

Participant flow — Overall Study
MilestoneTreatment Arm- ArtiFascia® PatchControl-Other Commercial Suturable Dural Substitute
Started6329
Treated6227
Completed5827
Not completed52

Outcome measures

PrimaryAbsence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging.

The primary end point will be assessed by evaluating the absence of cerebrospinal fluid fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging and physical examination of the surgical site.

Time frame:
6 month.
Reported as:
Count of participants · Participants
Absence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging.
ParticipantsControl-Other Commercial Suturable Dural SubstituteTreatment Arm-ArtiFascia® Graft
Presence of cerebrospinal fluid fistula and Pseudomeningocele00
No events of cerebrospinal fluid fistula and Pseudomeningocele2758
SecondaryWound Healing Assessment

Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.

Time frame:
6 month follow-up

Results for this outcome have not been posted.

SecondaryDevice Handling Characteristics as Reported by a User Experience Questionnaire

The following scoring system was used for the evaluation: 1\) Device ease of use, suturing and cutting were evaluated on a scale of 1=Easy to 5=Difficult. 2) Device strength and seal quality (during implantation) were scored on scale of 1=Low to 5=High.

Time frame:
On the day of the surgical procedure

Results for this outcome have not been posted.

SecondaryRadiological Imaging at 6 Months for Additional Findings at Implant Site

The rate of each of the following: Extracerebral fluid accumulation, pseudomeningocele, adhesion formation, brain edema adjacent to device implant site, abnormal thickening at implantation site and new membrane (scar) formation.

Time frame:
6 month follow-up
Reported as:
Count of participants · Participants
Radiological Imaging at 6 Months for Additional Findings at Implant Site
ParticipantsTreatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural Substitute
Present measures13
No findings presence5724

Adverse events

Collected over 2.5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm-ArtiFascia® Graft1/63 (1.6%)9/63 (14.3%)26/63 (41.3%)
Control-Other Commercial Suturable Dural Substitute0/29 (0%)3/29 (10.3%)15/29 (51.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTreatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural Substitute
Light chain diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/631/29
SeizureNervous system disorders0/631/29
VasospasmVascular disorders0/631/29
Facial paresisNervous system disorders1/630/29
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/630/29
Neoplasm of orbitNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/630/29
Cerebral haemorrhageNervous system disorders1/630/29
Extradural abscessInfections and infestations1/630/29
PneumoniaInfections and infestations1/630/29
Cardio-respiratory arrestCardiac disorders1/630/29
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTreatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural Substitute
EpilepsyNervous system disorders3/630/29
Facial paresisNervous system disorders0/631/29
Taste disorderNervous system disorders0/631/29
Eye swellingEye disorders0/631/29
Cerebrospinal fluid leakageNervous system disorders0/631/29
InflammationGeneral disorders0/631/29
Muscular weaknessMusculoskeletal and connective tissue disorders0/631/29
HeadacheNervous system disorders0/631/29
EpilepsyNervous system disorders0/631/29
HaemorrhageVascular disorders0/631/29

Baseline characteristics

Men and women between the ages of 18-75 scheduled for an elective cranial surgery that requires dural repair, meet all the inclusion and none of the exclusion criteria.

Age, Categorical
Age, Categorical(Participants)Treatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural SubstituteTotal
<=18 years011
Between 18 and 65 years482371
>=65 years15520
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural SubstituteTotal
Female432164
Male20828
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural SubstituteTotal
Hispanic or Latino14418
Not Hispanic or Latino492574
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural SubstituteTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White622991
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Treatment Arm-ArtiFascia® GraftControl-Other Commercial Suturable Dural SubstituteTotal
Belgium325
Czechia19928
Poland281240
Spain13619
08

Study locations

9 sites
  • Ziekenhuis Oost-Limburg
    Genk, B-3600, Belgium
  • St. Anne's University Hospital Brno
    Brno, 656 91, Czechia
  • Neurochirurgická klinika Přednosta FN Olomouc
    Olomouc, 779 00, Czechia
  • Rabin Medical Center (Beilinson, Hasharon)
    Petah Tikva, 49100, Israel
  • Medical University of Gdańsk
    Gdansk, 80-214, Poland
  • Barlicki University Hospital
    Lodz, 90-153, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de Bellvitge
    Barcelona, 09807, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Nov 2022, 33 months.

Results were first posted in Aug 2025, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 30, 2019
StartActual
Jan 7, 2020
Primary completionActual
Nov 1, 2022
CompletionActual
Nov 1, 2022
Results first posted
Aug 19, 2025
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04145544
Lead sponsor
Nurami Medical Ltd
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Jan 7, 2020
Primary completion
Nov 1, 2022
Completion
Nov 1, 2022
Results posted
Aug 19, 2025
Last update
Aug 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion